Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke Patients (Crypto PulseON)

To evaluate the usability of the Pulse ON wearable device in patients with cryptogenic stroke/TIA

Studieoversikt

Detaljert beskrivelse

The research project aims to evaluate the usability of a new device for detecting heart rhythm disturbances, especially atrial fibrillation (AF) in people who have had a stroke or mini-stroke (transient ischaemic attack [TIA]) of unknown cause (cryptogenic stroke). AF can be a major cause of disabling strokes and AF-related stroke risk is significantly reduced by starting specific blood thinners called anticoagulants.

Stroke is a major public health concern worldwide, with approximately 100,000 cases annually in the UK alone, making it a leading cause of death and disability. Around 38,000 stroke-related deaths occur each year, and many survivors experience significant long-term impairment. The vast majority (~90%) are ischaemic strokes, yet in 20-40% of cases, no definitive underlying cause is identified, despite extensive evaluation. These cryptogenic stroke cases remain a diagnostic challenge. Cryptogenic strokes are more common in younger stroke patients (<60 years) but can affect all age groups.

AF is the most common arrhythmia and a well-established cause of ischaemic stroke, responsible for 15-30% of cases. However, in cryptogenic stroke, AF often goes undiagnosed because it can come and go (i.e. is paroxysmal) and can be asymptomatic in nature, with episodes that can last for short periods of time but carry high risk of stroke. Early and accurate diagnosis of AF is crucial, as clinical trials have demonstrated the efficacy of oral anticoagulation in significantly reducing stroke risk. Thus, identifying AF in cryptogenic stroke patients can directly impact management by shifting treatment towards anticoagulation.

Background. Detecting AF in cryptogenic stroke is a major challenge and many methods fail to capture episodes of AF that come and go (paroxysmal). Conventional AF detection methods, such as in-hospital cardiac monitoring, serial ECGs, Holter monitors, external event recorders, wearable devices and implantable loop recorders (ILRs), vary in effectiveness. ILRs are small devices (the size of a pen-lid) implanted under the skin of the left chest wall and have a battery life of around three years. They have demonstrated superior diagnostic sensitivity, as highlighted in the CRYSTAL-AF trial, which showed their advantage over standard monitoring in cryptogenic stroke (AF detection rate of 12.4% for ILRs vs 2% for standard monitoring at 12 months). However, ILRs are invasive (which comes with its own procedure-related risks), costly, and may not be suitable for all patients.2 We want to evaluate a different type of AF detection device (the PulseON Arrhythmia Monitor System) that is not currently used in standard care, one that's wrist worn and non-invasive.

Proposed trial We propose a single centre, single arm feasibility pilot study designed to evaluate how practical and user friendly it is for participants to use the PulseON Arrhythmia Monitor System for detecting AF in addition to their normal standard of care. The study will explore whether participants can wear the device as intended, respond to alerts and successfully carry out ECG recordings using the system, whilst capturing their user experience and having their heart tracings closely monitored by health care professionals.

Trial population At UHCW NHS Trust, we manage approximately 1,400 strokes annually (with 350 classified as cryptogenic), many of whom will need to be monitored for AF. While most patients undergo Holter monitoring for AF, a smaller subset receive ILRs but their use is limited due their cost and invasive nature. The introduction of this PulseON device could significantly enhance AF detection, improving patient outcomes, be more cost-effective and optimise resource utilisation within our hospital and the broader NHS. We plan to evaluate whether cardiac monitoring with the PulseON system is feasible in patients with cryptogenic stroke/TIA. This evaluation project may inform wider research into this device and potential NHS implementation.

Treatment / Intervention We aim to recruit twelve patients who have experienced a cryptogenic ischaemic stroke or TIA within the past six months for this project. All patients who participate in the project will receive conventional standard of care investigations (Holter monitoring or ILR) in addition to the PulseON Arrhythmia monitoring system. The data collected will include experience of device usability via an MS forms questionnaire and a follow-up patient interview, baseline demographics, usability data and any newly detected arrhythmia observed from the heart tracing data, in particular AF (defined as an episode of AF lasting >30seconds). Any arrhythmia documented from the PulseON device will be uploaded and stored in an encrypted and secure cloud-based server.

Participants heart tracing data will be collected and reviewed by a suitably qualified healthcare professional within the study team (primarily the Principal Investigator).The reviewer will assess any detected cardiac events to determine their clinical significance and, when appropriate, will escalate relevant findings to the participant's clinical care team. This process ensures that any new or emerging information arising from the study is used to support and inform the provision of standard clinical care for participants.

Studietype

Observasjonsmessig

Registrering (Antatt)

12

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Coventry, Storbritannia, CV2 2DX
        • Rekruttering
        • University Hospital Coventry & Warwickshire NHS Trust

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients diagnosed with cryptogenic stroke/TIA

Beskrivelse

Inclusion Criteria:

  • Adult patients (>18yrs old) diagnosed with cryptogenic stroke / TIA
  • Baseline electrocardiogram (ECG), Holter monitor and echocardiogram as part of the standard of care cardiac work-up in the diagnosis of cryptogenic stroke

Exclusion Criteria:

  • Patients unwilling or unable to wear the PulseON arrhythmia detection device.
  • Known pre-existing AF or atrial arrhythmia diagnosis.
  • Participants without capacity will be excluded from this study.
  • Participants who are pregnant will be excluded from this study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Usability & Feasibility of PulseON wearable device
Tidsramme: 1 month minimum

We will collect patient questionnaires and perform patient interviews to gather data on the PulseON device for usability and feasibility data.

Formal feedback from health professionals who follow up the trial participants via the PulseON arrhythmia monitoring system online will be obtained.

1 month minimum

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The prevalence of AF in people who have had cryptogenic ischaemic stroke or TIA.
Tidsramme: 1 month

The ability of Pulse ON in detecting AF on ECG and how it differs from the standard of care (ECG, Holter monitoring or ILR)

1 month
Baseline characteristics of cohort
Tidsramme: 1 month

Baseline demographic and clinical characteristics

1 month

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Faizel Osman, University Hospital Coventry & Warwickshire
  • Hovedetterforsker: Ven G Lim, University Hospital Coventry & Warwickshire

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. september 2026

Primær fullføring (Antatt)

1. januar 2027

Studiet fullført (Antatt)

1. mars 2027

Datoer for studieregistrering

Først innsendt

11. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere